Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Colorectal Cancer and Metabolism.

Brown RE, Short SP, Williams CS.

Curr Colorectal Cancer Rep. 2018 Dec;14(6):226-241. doi: 10.1007/s11888-018-0420-y. Epub 2018 Nov 16.

PMID:
31406492
2.

Correction: Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma.

Short SP, Barrett CW, Stengel KR, Revetta FL, Choksi YA, Coburn LA, Lintel MK, McDonough EM, Washington MK, Wilson KT, Prokhortchouk E, Chen X, Hiebert SW, Reynolds AB, Williams CS.

Oncogene. 2019 Jun;38(25):5107. doi: 10.1038/s41388-019-0829-z.

PMID:
31068667
3.

Kaiso is required for MTG16-dependent effects on colitis-associated carcinoma.

Short SP, Barrett CW, Stengel KR, Revetta FL, Choksi YA, Coburn LA, Lintel MK, McDonough EM, Washington MK, Wilson KT, Prokhortchouk E, Chen X, Hiebert SW, Reynolds AB, Williams CS.

Oncogene. 2019 Jun;38(25):5091-5106. doi: 10.1038/s41388-019-0777-7. Epub 2019 Mar 11. Erratum in: Oncogene. 2019 May 8;:.

PMID:
30858547
4.

Blood vessel epicardial substance (BVES) reduces LRP6 receptor and cytoplasmic -catenin levels to modulate Wnt signaling and intestinal homeostasis.

Thompson JJ, Short SP, Parang B, Brown RE, Li C, Ng VH, Saito-Diaz K, Choksi YA, Washington MK, Smith JJ, Fingleton B, Brand T, Lee E, Coffey RJ, Williams CS.

Carcinogenesis. 2019 Jan 23. doi: 10.1093/carcin/bgz007. [Epub ahead of print]

PMID:
30689807
5.

Serine Threonine Kinase 17A Maintains the Epithelial State in Colorectal Cancer Cells.

Short SP, Thompson JJ, Bilotta AJ, Chen X, Revetta FL, Washington MK, Williams CS.

Mol Cancer Res. 2019 Apr;17(4):882-894. doi: 10.1158/1541-7786.MCR-18-0990. Epub 2019 Jan 17.

PMID:
30655319
6.

BVES is required for maintenance of colonic epithelial integrity in experimental colitis by modifying intestinal permeability.

Choksi YA, Reddy VK, Singh K, Barrett CW, Short SP, Parang B, Keating CE, Thompson JJ, Verriere TG, Brown RE, Piazuelo MB, Bader DM, Washington MK, Mittal MK, Brand T, Gobert AP, Coburn LA, Wilson KT, Williams CS.

Mucosal Immunol. 2018 Sep;11(5):1363-1374. doi: 10.1038/s41385-018-0043-2. Epub 2018 Jun 15.

7.

Roles for selenium and selenoprotein P in the development, progression, and prevention of intestinal disease.

Short SP, Pilat JM, Williams CS.

Free Radic Biol Med. 2018 Nov 1;127:26-35. doi: 10.1016/j.freeradbiomed.2018.05.066. Epub 2018 May 17. Review.

PMID:
29778465
8.

Reovirus-Induced Apoptosis in the Intestine Limits Establishment of Enteric Infection.

Brown JJ, Short SP, Stencel-Baerenwald J, Urbanek K, Pruijssers AJ, McAllister N, Ikizler M, Taylor G, Aravamudhan P, Khomandiak S, Jabri B, Williams CS, Dermody TS.

J Virol. 2018 Apr 27;92(10). pii: e02062-17. doi: 10.1128/JVI.02062-17. Print 2018 May 15.

9.

Using 3D Organoid Cultures to Model Intestinal Physiology and Colorectal Cancer.

Short SP, Costacurta PW, Williams CS.

Curr Colorectal Cancer Rep. 2017 Jun;13(3):183-191. doi: 10.1007/s11888-017-0363-8. Epub 2017 Apr 18.

10.

p120-Catenin is an obligate haploinsufficient tumor suppressor in intestinal neoplasia.

Short SP, Kondo J, Smalley-Freed WG, Takeda H, Dohn MR, Powell AE, Carnahan RH, Washington MK, Tripathi M, Payne DM, Jenkins NA, Copeland NG, Coffey RJ, Reynolds AB.

J Clin Invest. 2017 Dec 1;127(12):4462-4476. doi: 10.1172/JCI77217. Epub 2017 Nov 13.

11.

Selenoproteins in Tumorigenesis and Cancer Progression.

Short SP, Williams CS.

Adv Cancer Res. 2017;136:49-83. doi: 10.1016/bs.acr.2017.08.002. Review.

12.

MTG16 is a tumor suppressor in colitis-associated carcinoma.

McDonough EM, Barrett CW, Parang B, Mittal MK, Smith JJ, Bradley AM, Choksi YA, Coburn LA, Short SP, Thompson JJ, Zhang B, Poindexter SV, Fischer MA, Chen X, Li J, Revetta FL, Naik R, Washington MK, Rosen MJ, Hiebert SW, Wilson KT, Williams CS.

JCI Insight. 2017 Aug 17;2(16). pii: 78210. doi: 10.1172/jci.insight.78210. eCollection 2017 Aug 17.

13.

BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis.

Parang B, Kaz AM, Barrett CW, Short SP, Ning W, Keating CE, Mittal MK, Naik RD, Washington MK, Revetta FL, Smith JJ, Chen X, Wilson KT, Brand T, Bader DM, Tansey WP, Chen R, Brentnall TA, Grady WM, Williams CS.

Gut. 2017 May;66(5):852-862. doi: 10.1136/gutjnl-2015-310255. Epub 2016 Jan 14.

14.

Interleukin-22 drives nitric oxide-dependent DNA damage and dysplasia in a murine model of colitis-associated cancer.

Wang C, Gong G, Sheh A, Muthupalani S, Bryant EM, Puglisi DA, Holcombe H, Conaway EA, Parry NAP, Bakthavatchalu V, Short SP, Williams CS, Wogan GN, Tannenbaum SR, Fox JG, Horwitz BH.

Mucosal Immunol. 2017 Nov;10(6):1504-1517. doi: 10.1038/mi.2017.9. Epub 2017 Feb 15.

15.

Selenoproteins and oxidative stress-induced inflammatory tumorigenesis in the gut.

Barrett CW, Short SP, Williams CS.

Cell Mol Life Sci. 2017 Feb;74(4):607-616. doi: 10.1007/s00018-016-2339-2. Epub 2016 Aug 25. Review.

16.

Whole-mount Enteroid Proliferation Staining.

Barrett CW, Short SP, Choksi YA, Williams CS.

Bio Protoc. 2016 Jun 20;6(12). pii: e1837. doi: 10.21769/BioProtoc.1837.

17.

Selenoprotein P in colitis-associated carcinoma.

Short SP, Whitten-Barrett C, Williams CS.

Mol Cell Oncol. 2015 Jul 29;3(3):e1075094. doi: 10.1080/23723556.2015.1075094. eCollection 2016 May.

18.

Myeloid translocation genes differentially regulate colorectal cancer programs.

Parang B, Bradley AM, Mittal MK, Short SP, Thompson JJ, Barrett CW, Naik RD, Bilotta AJ, Washington MK, Revetta FL, Smith JJ, Chen X, Wilson KT, Hiebert SW, Williams CS.

Oncogene. 2016 Dec 8;35(49):6341-6349. doi: 10.1038/onc.2016.167. Epub 2016 Jun 6.

19.

BVES Regulates Intestinal Stem Cell Programs and Intestinal Crypt Viability after Radiation.

Reddy VK, Short SP, Barrett CW, Mittal MK, Keating CE, Thompson JJ, Harris EI, Revetta F, Bader DM, Brand T, Washington MK, Williams CS.

Stem Cells. 2016 Jun;34(6):1626-36. doi: 10.1002/stem.2307. Epub 2016 Mar 15.

20.

Selenoprotein P influences colitis-induced tumorigenesis by mediating stemness and oxidative damage.

Barrett CW, Reddy VK, Short SP, Motley AK, Lintel MK, Bradley AM, Freeman T, Vallance J, Ning W, Parang B, Poindexter SV, Fingleton B, Chen X, Washington MK, Wilson KT, Shroyer NF, Hill KE, Burk RF, Williams CS.

J Clin Invest. 2015 Jul 1;125(7):2646-60. doi: 10.1172/JCI76099. Epub 2015 Jun 8.

21.

The transcriptional corepressor MTGR1 regulates intestinal secretory lineage allocation.

Parang B, Rosenblatt D, Williams AD, Washington MK, Revetta F, Short SP, Reddy VK, Hunt A, Shroyer NF, Engel ME, Hiebert SW, Williams CS.

FASEB J. 2015 Mar;29(3):786-95. doi: 10.1096/fj.14-254284. Epub 2014 Nov 14.

22.

Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.

Ciombor KK, Feng Y, Benson AB 3rd, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, Richmond A, Berlin J.

Invest New Drugs. 2014 Oct;32(5):1017-27. doi: 10.1007/s10637-014-0111-8. Epub 2014 Jun 4.

23.

Kaiso directs the transcriptional corepressor MTG16 to the Kaiso binding site in target promoters.

Barrett CW, Smith JJ, Lu LC, Markham N, Stengel KR, Short SP, Zhang B, Hunt AA, Fingleton BM, Carnahan RH, Engel ME, Chen X, Beauchamp RD, Wilson KT, Hiebert SW, Reynolds AB, Williams CS.

PLoS One. 2012;7(12):e51205. doi: 10.1371/journal.pone.0051205. Epub 2012 Dec 12.

24.

RAF265 inhibits the growth of advanced human melanoma tumors.

Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A.

Clin Cancer Res. 2012 Apr 15;18(8):2184-98. doi: 10.1158/1078-0432.CCR-11-1122. Epub 2012 Feb 20. Erratum in: Clin Cancer Res. 2012 Aug 15;18(16):4475.

25.

Adenoma formation following limited ablation of p120-catenin in the mouse intestine.

Smalley-Freed WG, Efimov A, Short SP, Jia P, Zhao Z, Washington MK, Robine S, Coffey RJ, Reynolds AB.

PLoS One. 2011;6(5):e19880. doi: 10.1371/journal.pone.0019880. Epub 2011 May 17.

26.

Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Rhodes LV, Short SP, Neel NF, Salvo VA, Zhu Y, Elliott S, Wei Y, Yu D, Sun M, Muir SE, Fonseca JP, Bratton MR, Segar C, Tilghman SL, Sobolik-Delmaire T, Horton LW, Zaja-Milatovic S, Collins-Burow BM, Wadsworth S, Beckman BS, Wood CE, Fuqua SA, Nephew KP, Dent P, Worthylake RA, Curiel TJ, Hung MC, Richmond A, Burow ME.

Cancer Res. 2011 Jan 15;71(2):603-13. doi: 10.1158/0008-5472.CAN-10-3185. Epub 2010 Dec 1. Erratum in: Cancer Res. 2011 May 1;71(9):3432.

27.

p120-catenin is essential for maintenance of barrier function and intestinal homeostasis in mice.

Smalley-Freed WG, Efimov A, Burnett PE, Short SP, Davis MA, Gumucio DL, Washington MK, Coffey RJ, Reynolds AB.

J Clin Invest. 2010 Jun;120(6):1824-35. doi: 10.1172/JCI41414. Epub 2010 May 17.

28.

The hassle factor one year later: many changes, but many miles to go.

Short SP.

Internist. 1991 Oct;32(9):26-7, 29. No abstract available.

PMID:
10113943

Supplemental Content

Loading ...
Support Center